TSPAN32 and hematologic disorder: More recently, Qiu et al. (2023) [16] provided evidence linking TSPAN32 with reduced proliferative programs in human lymphocytes, and Scuderi et al. (2025) [17,26] showed its inverse association with oncogenic transcriptional networks in hematologic malignancies.